Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serplulimab + bevacizumab
- Development stage
- Phase 2
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination involves **serplulimab**, a novel anti-PD-1 monoclonal antibody, and **bevacizumab**, a monoclonal antibody targeting vascular endothelial growth factor (VEGF). The combination is used to treat cancers such as advanced hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC). Serplulimab works by inhibiting the PD-1/PD-L1 pathway, enhancing immune response against cancer cells. Bevacizumab inhibits angiogenesis by blocking VEGF, reducing tumor blood supply.
- Brand names
- Hansizhuang + Hanbeitai
- Other names
- bevacizumabserplulimabHLX04HLX-04HLX 04
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on serplulimab + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serplulimab + bevacizumab.